Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 11 of 11 for “"Filgrastim"”.

  1. Association between Filgrastim Biosimilar Availability and Changes in Claim Payments and Patient Out-of-Pocket Costs for Biologic Filgrastim Products

    … cost containment potential. The 2015 launch of filgrastim-sndz, the first U.S. biosimilar, provides a natural experiment in which to evaluate the biosimilar experience in the United States. In addition, an understanding of the adoption rate of a new biosimilar and its impact on referent biologic …

    jhu Repository record for Association between Filgrastim Biosimilar Availability and Changes in Claim Payments and Patient Out-of-Pocket Costs for Biologic Filgrastim Products (opens in a new tab)

  2. Biosimilar uptake in the United States: Examining state-level longitudinal trends in biosimilar filgrastim use and their association with biosimilar substitution policies

    … access to biologics. This quantifies biosimilar filgrastim uptake ratios at the state level, uses longitudinal trends to examine the presence of state sub-groups based on product use, and finally assesses the association between the status and content of state-level biosimilar substitution …

    washington Repository record for Biosimilar uptake in the United States: Examining state-level longitudinal trends in biosimilar filgrastim use and their association with biosimilar substitution policies (opens in a new tab)

  3. Economic Evaluation of Strategies to Prevent and Treat Febrile Neutropenia in Lymphoma Patients

    … were to quantify the cost-effectiveness of filgrastim and pegfilgrastim as primary prophylaxis against FN in NHL patients, to develop an algorithm for converting health-related quality of life data collected in non-Hodgkin lymphoma patients into preference-based health utility values, and to …

    toronto-retro Repository record for Economic Evaluation of Strategies to Prevent and Treat Febrile Neutropenia in Lymphoma Patients (opens in a new tab)

  4. Ρύθμιση πολλαπλασιασμού στελεχιαίων αιμοποιητικών κυττάρων (ΣΑΚ)

    … pharmacological preconditioned of UCB culturesby filgrastim agent already used in the clinical setting. In crucial cell populations implicated inthe promotion of functional engraftment, the progression of free survival rates (PFS), a markedincrease of 6.65 to 9.34 fold for UCB-MN and 35 to 49 fold …

    greece Repository record for Ρύθμιση πολλαπλασιασμού στελεχιαίων αιμοποιητικών κυττάρων (ΣΑΚ) (opens in a new tab)

  5. Challenges in the Pharmacokinetics of Therapeutic Proteins

    … study was performed with two model drugs: filgrastim and denosumab. Their published structural pharmacokinetic models and model parameters were employed in the simulations of plasma concentration-time profiles at different IV and SC doses. The bioavailability was calculated as the ratio of …

    tenn-hsc Repository record for Challenges in the Pharmacokinetics of Therapeutic Proteins (opens in a new tab)

  6. Apherese von CD34-positiven Vorläuferzellen unter Imatinibmesylat bei Patienten mit chronischer myeloischer Leukämie in kompletter zytogenetischer Remission

    … als 6 Monate zur Separation CD34+ Zellen mit Filgrastim mobilisiert, ohne dabei die Therapie mit Imatinib zu unterbrechen. Während der Therapie und Mobilisation wurden sowohl Blut- und Knochenmarksproben als auch die Stammzellapheresate zytogenetisch und molekulargenetisch untersucht. Es …

    fu-berlin Repository record for Apherese von CD34-positiven Vorläuferzellen unter Imatinibmesylat bei Patienten mit chronischer myeloischer Leukämie in kompletter zytogenetischer Remission (opens in a new tab)

  7. Effective chemotherapy support: a matter of timing and combining?

    … at times can be fatal. With the introduction of filgrastim, caregivers were provided with a useful tool to prevent chemotherapy-induced neutropenia, but also with an economic burden as granulocyte-colony stimulating factor (G-CSF) is expensive. Therefore, effective use of G-CSF is essential. We …

    radboud Repository record for Effective chemotherapy support: a matter of timing and combining? (opens in a new tab) Download PDF for Effective chemotherapy support: a matter of timing and combining? (opens in a new tab)

  8. Der Einfluss von Chemotherapien und G-CSF auf das Riechen und Schmecken beim Menschen

    … G-CSF wurde über 5–6 Tage (Lenograstim bzw. Filgrastim ± Plerixafor) verabreicht. Die Testmethoden umfassten einen Anamnesebogen zur Erfassung der subjektiven Wahrnehmung, Sniffing Sticks zur Testung der Riechfunktion und Schmecksprays zur Testung der Schmeckwahrnehmung. Die olfaktorische …

    qucosa-diss

  9. Biosimilars in the United States: Market Dynamics and Patient Out-of-Pocket Costs

    … (number of claims) for the following biologics: filgrastim, rituximab, infliximab, trastuzumab, pegfilgrastim, epoetin alfa, bevacizumab, and ranibizumab. We first characterized the markets descriptively, then used linear regression to assess the relationship between reference product market …

    washington Repository record for Biosimilars in the United States: Market Dynamics and Patient Out-of-Pocket Costs (opens in a new tab)

  10. Eicosanoid Regulation of Hematopoietic Stem and Progenitor Cell Function

    Adult hematopoietic stem cells (HSC) are routinely used to reconstitute hematopoiesis after myeloablation; however, transplantation efficacy and multilineage reconstitution can be limited by inadequate HSC number, or poor homing, engraftment or self-renewal. We have demonstrated that mouse and …

    iupui Repository record for Eicosanoid Regulation of Hematopoietic Stem and Progenitor Cell Function (opens in a new tab)